Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) saw a large increase in short interest in September. As of September 30th, there was short interest totalling 171,900 shares, an increase of 36.4% from the September 15th total of 126,000 shares. Based on an average daily volume of 400 shares, the short-interest ratio is currently 429.8 days.

Molecular Partners Stock Performance

Shares of MLLCF stock traded down $0.31 on Monday, hitting $5.98. 500 shares of the stock traded hands, compared to its average volume of 1,428. Molecular Partners has a 1-year low of $5.16 and a 1-year high of $32.00. The company's fifty day moving average is $5.83 and its 200 day moving average is $8.03.

Analysts Set New Price Targets

Separately, Credit Suisse Group cut their target price on Molecular Partners from CHF 8 to CHF 6 in a research report on Thursday, July 21st.

About Molecular Partners

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.

Read More

• Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
• Fisker is Entering a Critical Stage That Could Reward Investors
• The Bottom Is In For JPMorgan Chase & Co.
• The Institutions May Cap Gains In Steel Dynamics
• Watch These 3 Economic Reports to Impact Interest Rate Hikes
• Here are 3 Stocks That Benefit From a Strong U.S. Dollar

Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.